Summit stock jumps as FDA grants fast track tag for lung cancer therapy

seekingalpha10-04

Summit Therapeutics (NASDAQ:SMMT) shares rose as much as 25% in premarket trading on Friday after the company secured FDA’s Fast Track designation for the proposed use of its cancer drug, ivonescimab,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472793089?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","is_english":true,"pubTime":"2024-10-04 17:43","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2472793089","market":"sg","top_or_hot":-1,"title":"Summit stock jumps as FDA grants fast track tag for lung cancer therapy","media":"seekingalpha","content":"<div>\n<p>Summit Therapeutics (NASDAQ:SMMT) shares rose as much as 25% in premarket trading on Friday after the company secured FDA’s Fast Track designation for the proposed use of its cancer drug, ivonescimab,...</p>\n\n<a href=\"https://seekingalpha.com/news/4156358-summit-stock-jumps-as-fda-grants-fast-track-tag-for-lung-cancer-therapy\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit stock jumps as FDA grants fast track tag for lung cancer therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit stock jumps as FDA grants fast track tag for lung cancer therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-04 17:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4156358-summit-stock-jumps-as-fda-grants-fast-track-tag-for-lung-cancer-therapy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit Therapeutics (NASDAQ:SMMT) shares rose as much as 25% in premarket trading on Friday after the company secured FDA’s Fast Track designation for the proposed use of its cancer drug, ivonescimab,...</p>\n\n<a href=\"https://seekingalpha.com/news/4156358-summit-stock-jumps-as-fda-grants-fast-track-tag-for-lung-cancer-therapy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4156358-summit-stock-jumps-as-fda-grants-fast-track-tag-for-lung-cancer-therapy","article_id":"2472793089","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472793089","pubTimestamp":1728034999,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Summit Therapeutics  shares rose as much as 25% in premarket trading on Friday after the company secured FDA’s Fast Track designation for the proposed use of its cancer drug, ivonescimab, in combination with platinum-based chemotherapy for the treatment of advanced lung cancer. The combination therapy is intended for locally advanced or metastatic non-small cell lung cancer  with epidermal growth factor receptor  mutation in adults, who have experienced disease progression following EGFR-tyrosine kinase inhibitor therapy. Ivonescimab, an investigational bispecific antibody, was engineered by Akeso  and is currently engaged in multiple Phase III clinical trials. As part of a license deal signed in 2022, Summit  began the clinical development of ivonescimab in non-small cell lung cancer, commencing enrollment in 2023 in two multi-regional Phase III studies, HARMONi and HARMONi-3, with a plan to initiate HARMONi-7 in early 2025. HARMONi is designed with dual primary endpoints of progressi","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SMMT":"Summit Therapeutics PLC","AKESF":"AKESO INC.","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"FDA授予肺癌治疗快速通道标签，Summit股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKESF":0.9,"SMMT":0.9},"content_text":"Summit Therapeutics (NASDAQ:SMMT) shares rose as much as 25% in premarket trading on Friday after the company secured FDA’s Fast Track designation for the proposed use of its cancer drug, ivonescimab, in combination with platinum-based chemotherapy for the treatment of advanced lung cancer. The combination therapy is intended for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation in adults, who have experienced disease progression following EGFR-tyrosine kinase inhibitor therapy. Ivonescimab, an investigational bispecific antibody, was engineered by Akeso (OTCPK:AKESF) and is currently engaged in multiple Phase III clinical trials. As part of a license deal signed in 2022, Summit (SMMT) began the clinical development of ivonescimab in non-small cell lung cancer, commencing enrollment in 2023 in two multi-regional Phase III studies, HARMONi and HARMONi-3, with a plan to initiate HARMONi-7 in early 2025. HARMONi is designed with dual primary endpoints of progression-free survival and overall survival, with topline data expected in mid-2025. The Summit-sponsored trial, which has completed enrolling patients from sites in North America, Europe, and China, will evaluate ivonescimab plus chemotherapy compared to placebo plus chemotherapy in patients with EGFRm advanced lung cancer.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472793089"}